Using chemokine receptors to improve cancer immunotherapy: CCR4-targeted T cell fratricide

Chimeric antigen receptor T cell (CAR-T) therapy continues to be a powerful approach for treating relapsed-refractory hematological malignancies. Despite ongoing clinical success patients remain resistant to long-term benefits of CAR-T therapy.
Read More
TOP